These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 17352770)
1. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. Mallolas J; Sarasa M; Nomdedeu M; Soriano A; López-Púa Y; Blanco JL; Martínez E; Gatell JM HIV Med; 2007 Mar; 8(2):131-4. PubMed ID: 17352770 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin. Gausi K; Mugerwa H; Siccardi M; Montanha MC; Lamorde M; Wiesner L; D'Avolio A; McIlleron H; Wilkins E; De Nicolò A; Maartens G; Khoo S; Kityo C; Denti P; Waitt C Clin Infect Dis; 2024 May; 78(5):1246-1255. PubMed ID: 37982585 [TBL] [Abstract][Full Text] [Related]
3. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. McCance-Katz EF; Moody DE; Morse GD; Ma Q; DiFrancesco R; Friedland G; Pade P; Rainey PM Drug Alcohol Depend; 2007 Dec; 91(2-3):269-78. PubMed ID: 17643869 [TBL] [Abstract][Full Text] [Related]
4. Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. Zhang C; Denti P; Decloedt E; Maartens G; Karlsson MO; Simonsson US; McIlleron H Br J Clin Pharmacol; 2012 May; 73(5):758-67. PubMed ID: 22126409 [TBL] [Abstract][Full Text] [Related]
5. Atazanavir: its role in HIV treatment. Wood R Expert Rev Anti Infect Ther; 2008 Dec; 6(6):785-96. PubMed ID: 19053892 [TBL] [Abstract][Full Text] [Related]
6. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. Kiser JJ; Rutstein RM; Samson P; Graham B; Aldrovandi G; Mofenson LM; Smith E; Schnittman S; Fenton T; Brundage RC; Fletcher CV AIDS; 2011 Jul; 25(12):1489-96. PubMed ID: 21610486 [TBL] [Abstract][Full Text] [Related]
7. A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents. Ngara B; Zvada S; Chawana TD; Stray-Pedersen B; Nhachi CFB; Rusakaniko S BMC Pharmacol Toxicol; 2020 Aug; 21(1):58. PubMed ID: 32746923 [TBL] [Abstract][Full Text] [Related]
8. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. Siccardi M; D'Avolio A; Baietto L; Gibbons S; Sciandra M; Colucci D; Bonora S; Khoo S; Back DJ; Di Perri G; Owen A Clin Infect Dis; 2008 Nov; 47(9):1222-5. PubMed ID: 18831695 [TBL] [Abstract][Full Text] [Related]
9. Potential association between chia seeds use and low atazanavir trough concentrations in an HIV-infected patient. Cattaneo D; Pagano S; Beltrami M; Micheli V; Gervasoni C Eur J Clin Pharmacol; 2023 Aug; 79(8):1145-1146. PubMed ID: 37331988 [No Abstract] [Full Text] [Related]
10. Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Venuto CS; Lim J; Messing S; Hunt PW; McComsey GA; Morse GD Antivir Ther; 2018; 23(4):345-351. PubMed ID: 29171837 [TBL] [Abstract][Full Text] [Related]
11. Effect of rifampicin administration on CYP induction in a dermatomyositis patient with vasospastic angina attributable to nilmatrelvir/ritonavir-induced blood tacrolimus elevation: A case report. Akamatsu H; Kohno Y; Hashizume J; Nakagawa H; Kodama Y; Kawano H; Maemura K; Ohyama K J Infect Chemother; 2024 Sep; 30(9):928-933. PubMed ID: 38360184 [TBL] [Abstract][Full Text] [Related]
12. Association of Pharmacogenetic Markers With Atazanavir Exposure in HIV-Infected Women. Tamraz B; Huang Y; French AL; Kassaye S; Anastos K; Nowicki MJ; Gange S; Gustafson DR; Bacchetti P; Greenblatt RM; Hysi PG; Aouizerat BE; Clin Pharmacol Ther; 2020 Feb; 107(2):315-318. PubMed ID: 31562781 [No Abstract] [Full Text] [Related]
13. Synthetic and Clinical Perspectives of Evotaz: An Overview. Puri S; Yadav TT; Chouhan M; Kumar K Mini Rev Med Chem; 2024; 24(4):372-390. PubMed ID: 37424344 [TBL] [Abstract][Full Text] [Related]
15. Potential drug-drug interactions of frequently prescribed medications in long COVID detected by two electronic databases. Meakleartmongkol T; Tangpanithandee S; Vanavivit N; Jiso A; Pongchaikul P; Kirdlarp S; Khemawoot P; Nathisuwan S PLoS One; 2023; 18(11):e0293866. PubMed ID: 37972000 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals. Nwogu JN; Ma Q; Babalola CP; Adedeji WA; Morse GD; Taiwo B AIDS Res Treat; 2016; 2016():2587094. PubMed ID: 27777797 [TBL] [Abstract][Full Text] [Related]